All > Massachusetts Investigators

J. D. Chang, MD

Beth Israel Deaconess Medical Center

Boston, Massachusetts - 02215

CLINICAL TRIALS 1
CONDITIONS1
INTERVENTIONS2
SINCE2007

Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity

June 2007 - June 2013

Breast Neoplasms

Placebo

At1 Blocker Candesartan

Learn about TrialX Patient Recruitment services

Massimo Loda, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Suzanne Shusterman

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Childrens Hospital Boston, Dana-Farber Cancer Institute. Children's Hospital Boston

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute Dana Farber / Brigham and Women's Cancer Center Dana-Farber Cancer Institute, Center for Neuro-Oncology Dana-Farber Cancer Instiute

Lewis B. Silverman, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute and Children's Hospital Dana Faber Cancer Institute, Children's Hospital, Dept. of Pediatric Oncology Children's Hospital Boston Dana-Farber Cancer Institute

J. D. Chang, MD

Beth Israel Deaconess Medical Center

Massimo Loda, MD

Suzanne Shusterman

Patrick Y. Wen, MD

Lewis B. Silverman, MD

Kay Kehoe, Coordinator

Jennifer Brown, MD

Rachel A. Freedman

Edwin P. Alyea, MD

F. Stephen Hodi, MD

Beth A. Overmoyer, MD, FACP